[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"osteoarthritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:osteoarthritis":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,105,0,25,[9,43,71,100,129,156,186,209,233,258,286,308,334,354,378,410,439,459,481,508,542,567,592,618,646],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100620154","phase-3-efficacy-and-safety-of-eloralintide-ly3841136-in-participants-with-osteoarthritis-knee-pain-and-obesity-or-overweight-100620154",false,"NCT07353931","Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight","A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Osteoarthritis Knee Pain, and Obesity or Overweight (ENLIGHTEN-4)","ENLIGHTEN-4","Inclusion Criteria:\n\n* Have a body mass index (BMI) of 27 kilograms per square meter (kg\u002Fm²) or higher at screening\n* Have a stable body weight (less than 5% body weight change) for 90 days prior to screening\n* Have tried at least once to lose weight through diet but were unsuccessful\n* Have osteoarthritis of the knee and at least one of the following conditions:\n\n  * Be over 50 years old\n  * Have morning knee stiffness that lasts about 30 minutes\n  * Have a crackling or grinding sound or feeling in the knee\n\nExclusion Criteria:\n\n* Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed greater than 1 year before screening)\n* Have a prior or planned endoscopic procedure and\u002For device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)\n* Have type 1 diabetes, type 2 diabetes, or any other type of diabetes\n* Have an active knee infection\n* Have had within 90 days prior to screening:\n\n  * heart attack\n  * stroke\n  * coronary artery revascularization\n  * unstable angina, or\n  * hospitalization due to congestive heart failure\n* Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure\n* Have taken medications or alternative remedies intended for weight loss within 90 days of screening","ALL","18 Years",{"count":21,"type":22},900,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.",[28,29],"Osteoarthritis","Overweight or Obesity","RECRUITING","2026-08-20",{"date":33,"type":34},"2026-08-21","ACTUAL",{"date":36,"type":34},"2026-02-09",{"date":38,"type":22},"2028-05",{"name":40,"class":41},"Eli Lilly and Company","INDUSTRY",152,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":69,"locationsCount":70},"100604742","phase-3-a-study-of-orforglipron-ly3502970-in-participants-with-obesity-or-overweight-and-osteoarthritis-oa-of-the-knee-100604742","NCT07153471","A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee","A Phase 3 Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Trial","ATTAIN-OA PAIN","Inclusion Criteria:\n\n* Have a body mass index (BMI) of 27 kilograms per square meter (kg\u002Fm2) or higher at screening\n* Have tried at least once to lose weight through diet but were unsuccessful\n* Have osteoarthritis of the knee and at least one of the following conditions:\n\n  * Be over 50 years old\n  * Have morning knee stiffness that lasts about 30 minutes\n  * Have a crackling or grinding sound or feeling in the knee\n\nExclusion Criteria:\n\n* Have gained or lost more than 11 pounds within 90 days prior to screening\n* Have had a surgery for obesity or plan to have one in the next 18 months\n* Have an active knee infection\n* Have type 1 diabetes, type 2 diabetes, or any other type of diabetes\n* Have had a recent heart condition or New York Heart Association Functional Classification Class IV congestive heart failure\n* Have used any glucagon-like peptide-1 (GLP-1) receptor agonist medication within 180 days of screening",{"count":52,"type":22},800,[25],"The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2. Each study will see how well and safely orforglipron works in people with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 74 weeks.",[28],[57,58,59,60,61,62,63,64],"Arthritis","Overnutrition","Nutrition Disorder","Joint Diseases","Musculoskeletal Disease","Knee Degeneration","Osteoarthrosis","Obese",{"date":33,"type":34},{"date":67,"type":34},"2025-09-15",{"date":38,"type":22},{"name":40,"class":41},96,{"id":72,"slug":73,"hasResults":12,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":12,"sex":18,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100652840","efficacy--safety-of-fluoroquinolone-based-brucellosis-regimens-bruce-100652840","NCT07779629","Efficacy & Safety of Fluoroquinolone-Based Brucellosis Regimens (BRUCE)","A Prospective, Multicenter, Randomized, Open-Label, Parallel-Group Clinical Trial: Efficacy and Safety of Fluoroquinolone-Based Regimens for Uncomplicated and Osteoarticular Brucellosis (the BRUCE Study)","BRUCE","Inclusion Criteria:1. The diagnostic basis for confirmed cases of brucellosis is the \"Expert Consensus on the Diagnosis and Treatment of Brucellosis\" published by the Editorial Board of the Chinese Journal of Infectious Diseases in 2017 and the \"Diagnosis and Treatment Protocol for Brucellosis (2023 Edition)\".\n\n1. There is an epidemiological history, such as a history of contact with suspected or confirmed animals, patients, contaminated animal products, or cultures; living in an endemic area of brucellosis; or having a close relationship with the production, use, and research of vaccines.\n2. At the same time, there are the following relevant clinical manifestations: fever, hyperhidrosis, joint pain, headache, fatigue, anorexia, myalgia, weight loss, arthritis, spondylitis, meningitis, or focal organ involvement such as endocarditis, hepatosplenomegaly, orchitis, or epididymitis.\n3. In the serological screening, the Rose Bengal plate agglutination test is positive. For the tube agglutination test (SAT), the titer is 1:100 or higher with significant agglutination, or if the course of the disease is more than one year, the titer is 1:50 with significant agglutination or higher; or if there is a history of brucellosis vaccination within half a year, the titer reaches 1:100 with significant agglutination or higher. Accompanied by (or) positive culture of Brucella in the patient's blood, body fluids, or tissues. Or positive NGS detection of Brucella.\n\n2\\. On the basis of the above - mentioned diagnosis of brucellosis, spondylitis and sacroiliitis are also present.\n\nExclusion Criteria:1. Those with comorbid tuberculosis, severe cardiopulmonary dysfunction, advanced tumors, central nervous system diseases (such as a history of epilepsy), or other systemic diseases; 2. Those with comorbid neurological or mental disorders who are unable or unwilling to cooperate; 3. Pregnant or lactating women, or those with a recent plan to have children; 4. Patients with a history of using glucocorticoids, immunomodulators, anti - tuberculosis drugs, etc. within the past 3 months; 5. Patients with missing important information or abnormal mental states.","16 Years","75 Years",{"count":82,"type":22},350,[84],"NA","Brucellosis is a globally distributed zoonosis with persistent clinical management challenges. The World Health Organization(WHO)-recommended doxycycline-rifampin (DOX-RIF) dual regimen may drive rifampin-associated antimicrobial resistance across all brucellosis-endemic regions. Patients with osteoarticular brucellosis require long-term intravenous ceftriaxone triple therapy, which is linked to poor treatment adherence due to repeated hospital visits and outpatient care demands. Fluoroquinolones (levofloxacin \\[LVX\\], moxifloxacin \\[MXF\\]) exert excellent anti-Brucella activity and superior bone-joint penetration, yet high-quality multicenter prospective data comparing rifampin-sparing LVX-DOX\u002FMXF-DOX dual regimens against standard RIF-DOX remain rarely reported. Existing comparative studies are limited to small single-center retrospective cohorts or trials pairing rifampin with fluoroquinolones rather than rifampin-free dual oral therapy. This multicenter prospective parallel-cohort protocol includes Module I (non-inferiority design) : 200 patients with uncomplicated acute brucellosis receiving 6-week dual oral therapy; and Module II (non-inferiority design) : 150 patients with imaging-confirmed osteoarticular brucellosis receiving 12-week triple therapy. Clinical data of standardized clinical, laboratory, radiologic, and subsequent longitudinal follow-up data will be collected via centralized electronic data capture. Primary endpoints include clinical and microbiological cure rates at 6 weeks (Module I) and 12 weeks (Module II). Secondary endpoints measure 24-week post treatment recurrence, 24- and 48-week radiologic improvement for osteoarticular disease, and adverse events during treatment. Multivariate regression and Cox models will identify independent prognostic factors and construct a generalizable recurrence risk prediction model. This clinical trial fills a critical evidence gap for oral fluoroquinolone-based regimens, with findings intended to supply supplementary brucellosis treatment approach, reduce rifampin resistance pressure, and eliminate reliance on prolonged parenteral therapy for complicated brucellosis.",[87,28],"Brucellosis",[89],"brucellosis; osteoarticular brucellosis; fluoroquinolones; antimicrobial treatment; prospective cohort study","NOT_YET_RECRUITING","2026-08-18",{"date":33,"type":34},{"date":94,"type":22},"2026-09-01",{"date":96,"type":22},"2027-12",{"name":98,"class":99},"The First Affiliated Hospital of Shihezi University","OTHER",{"id":101,"slug":102,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":23,"phases":108,"briefSummary":110,"conditions":111,"keywords":115,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":126,"locationsCount":128},"100562476","phase-4-systemic-oral-glucocorticoids-for-the-treatment-of-acute-osteoarthritis-pain-in-the-emergency-department-100562476","NCT06603662","Systemic Oral Glucocorticoids for the Treatment of Acute Osteoarthritis Pain in the Emergency Department","Inclusion Criteria:\n\n* Age ≥18 years\n* Acute monoarticular arthritic joint pain affecting native knee, hip, or shoulder presumed to be related to osteoarthritis\n* Acute pain above baseline starting less than 72 hour prior to ED visit\n* Planned discharge from the ED\n* History of osteoarthritis of the affected joint based on radiography performed at index visit or prior available imaging\n\nExclusion Criteria:\n\n* Trauma to the affected joint within 30 days\n* Injection of affected joint within 60 days\n* Prior arthroplasty of the affected joint\n* History of coronary artery disease, severe gastrointestinal bleeding, gastric\u002Fpeptic ulcer disease, chronic kidney disease with GFR less than 30, or platelet disorders (including von Willebrand disease, hemophilia, severe thrombocytopenia with platelets less than 50 k\u002FmcL)\n* Joint pain suspected to be related to rheumatoid arthritis, gout, septic arthritis, or other non-osteoarthritis autoimmune\u002Finflammatory\u002Finfectious arthritis\n* Chronic\u002Fbaseline use of glucocorticoids (greater than 5 mg daily prednisone or equivalent within previous 7 days) or NSAIDs (daily use for more than 2 days prior to presentation)\n* Daily prescription opioid use or active opioid use disorder\n* Illicit drug use\n* Known allergy\u002Fintolerance to ibuprofen\u002FNSAIDs, prednisone, dexamethasone, or other medication precluding ability to participate in one or more study arms\n* Other contraindications to ibuprofen\u002FNSAIDs or glucocorticoids\n* Planned hospitalization from the ED\n* Pregnancy\n* Incarceration\n* Inability to provide informed consent\n* Other conditions that would preclude compliance with the study protocol and medication dosing",{"count":107,"type":22},192,[109],"PHASE4","The purpose of this clinical trial is to compare the analgesic effects (relief of pain) of glucocorticoids (steroids) and pain medication versus pain medication alone in adult patients presenting to the emergency department with joint pain due to osteoarthritis. Steroids are drugs that can reduce inflammation and are used commonly for many different medical conditions.\n\nIn brief, the central aims of the study are to:\n\n1. Assess the efficacy of adding oral glucocorticoid medications to the standard pain medications used to treat the pain of osteoarthritis.\n2. Assess the safety and tolerability of oral glucocorticoid medication for the short-term treatment of osteoarthritis pain.\n\nWe hypothesize that: 1) The addition of glucocorticoids to standard pain medications will improve reported pain scores at 3 days following the initiation of treatment compared to standard pain medications alone and 2) The use of glucocorticoids will be well tolerated.\n\nParticipants in the study will be randomized (like flipping a coin) into one of three groups:\n\n1. Study Group 1 (Control) receiving placebo pills (no active ingredient) once a day for 5 days, plus ibuprofen (pain medication) for 5 days.\n2. Study Group 2 (Intervention A) who will receive prednisone (steroid) once a day for 5 days, plus ibuprofen (pain medication) for 5 days.\n3. Study Group 3 (Intervention B) who will receive one dose of dexamethasone (steroid) followed by placebo pills (no active ingredient) once a day for 4 days, plus ibuprofen (pain medication) for 5 days.\n\nIn all groups, acetaminophen (a different pain medication) can be taken as needed for pain that is not controlled with ibuprofen.\n\nParticipants will:\n\n* Receive follow up phone calls at 1, 3, 7 and 14 days.\n* Report pain scores related to joint pain.\n* Report the number of pills taken of the various medications used in the study.\n* Report any adverse events incurred during the follow up period.",[28,112,113,114],"Osteoarthritis (OA) of the Knee","Osteoarthritis (OA) of the Shoulder","Osteoarthritis (OA) of the Hip",[116,117,118,119],"osteoarthritis","acute pain","glucocorticosteroids","emergency department","2026-08-17",{"date":122,"type":34},"2026-08-19",{"date":124,"type":34},"2025-02-24",{"date":96,"type":22},{"name":127,"class":99},"WellSpan Health",1,{"id":130,"slug":131,"hasResults":12,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":139,"phases":4,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":155},"100495566","osteomics-identifying-regulators-of-bone-homeostasis-100495566","NCT05732870","OSTEOMICS: Identifying Regulators of Bone Homeostasis","OSTEOMICS","Inclusion Criteria:\n\n1. Patients with osteoarthritis undergoing total joint arthroplasty, osteotomy or arthrodesis of any joint (including hip, knee, shoulder, wrist, elbow, ankle).\n2. Patient with fractured neck of femurs undergoing hemiarthroplasty or total hip arthroplasty, or other internal fixation procedure.\n3. Patients undergoing acute low-velocity or fragility fracture fixation surgery.\n4. Patients aged between 18-110 years old with capacity to consent.\n\nSince deteriorating bone health including diseases like osteoporosis are primarily conditions of older age there is no practical upper age-limit. However, study involvement is limited by suitability for surgery which encompasses multiple factors considered on an individual case basis including age, frailty, comorbidities, baseline mobility, renal function and ability to consent (for instance due to dementia or delirium).\n\nWe note that our inclusion criteria is purposefully broad as we aim to deduce trends across a wide range of conditions and backgrounds.\n\nExclusion Criteria:\n\n1. Patients unable to provide informed consent.\n2. Patients with suspected\u002Festablished underlying malignancy.\n3. Patients with suspected\u002Festablished osteomyelitis.\n4. Patients with suspected\u002Festablished bloodborne disease\n5. Patients who are currently a subject of a clinical trial involving an investigational medicinal product.","110 Years",{"count":138,"type":22},2000,"OBSERVATIONAL","Diseases of bone associated with ageing, including osteoporosis (OP) and osteoarthritis (OA), reduce bone mass, bone strength and joint integrity. Current non-surgical approaches are limited to pharmaceutical agents that are not disease modifying and have poor patient tolerability due to side effect profiles. Developing a fundamental understanding of cellular bone homeostasis, including how key cell types affect tissue health, and offering novel therapeutic targets for prevention of bone disease is therefore essential. This is the focus of OSTEOMICS.\n\nA number of factors have been linked to increased risk of bone disease, including genetic predisposition, diet, smoking, ageing, autoimmune disorders and endocrine disorders. In our study, we will recruit patients undergoing elective and non-elective orthopaedic surgery and obtain surgical bone waste for analysis. This will capture a cohort of patients with bone disorders like OP and OA, in addition to patients without overt clinical bone disease. We will study the relationship between the molecular biology of bone cells, bone structure, genetics (DNA) and environmental factors with the aim of identifying and validating novel therapeutic targets.\n\nWe will leverage modern single cell technologies to understand the diversity of cell types found in bone. These technologies have now led to the characterisation of virtually every tissue in the body, however bone and bone-adjacent tissues are massively underrepresented due to the anatomical location and underlying technical challenges. Early protocols to demineralise bone and perform single cell profiling have now been developed. We will systematically scale up these efforts to observe how genetic variation at the population level leads to alterations in bone structure and quality.\n\nOver the next 10 years, we will generate data to comprehensively characterise bone across health and disease, use machine learning to drive analysis, and experimentally validate hypotheses - which will ultimately contribute to developing the next generation of therapeutic agents.",[142,28,143,144,145],"Osteoporosis","Bone Diseases","Bone Fracture","Bone Marrow Disease","2026-08-12",{"date":148,"type":34},"2026-08-14",{"date":150,"type":34},"2023-01-12",{"date":152,"type":22},"2032-12",{"name":154,"class":41},"Relation Therapeutics",8,{"id":157,"slug":158,"hasResults":12,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":12,"sex":18,"minAge":163,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":23,"phases":167,"briefSummary":168,"conditions":169,"keywords":172,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":128},"100541300","comparing-efficiency-of-mirogabalin-and-pregabalin-in-primary-tka-100541300","NCT06328062","Comparing Efficiency of Mirogabalin and Pregabalin in Primary TKA","Comparison Efficacy of Mirogabalin and Pregabalin in Total Knee Arthroplasty. a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age 50-85 years old\n2. Unilateral primary osteoarthritis undergoing primary TKA\n3. ASA I-III\n\nExclusion Criteria:\n\n1. GFR \\<60\n2. Allergy to drug in this study\n3. Cannot underwent spinal anesthesia and adductor canal block\n4. Taking gabapentinoid within 3 months before surgery\n5. History of previous knee surgery\n6. Severe liver disease","50 Years","85 Years",{"count":166,"type":22},80,[84],"The goal of this RCT is to compare efficacy between mirogabalin and pregabalin in pain reducing after unilateral primary total knee arthroplasty.\n\nThe main question\\[s\\] it aims to answer are:\n\n• Does mirogabalin have better pain reduction than pregabalin after unilateral primary total knee arthroplasty.\n\nParticipants will randomized to mirogabalin or pregabalin group and will take the drug for 2 weeks after TKA. Researchers will compare to pregabalin group to see pain and functional outcomes after TKA.",[170,28,171],"Pain Postoperative","Total Knee Arthroplasty",[173,174,175,176],"mirogabalin","pregabalin","pain postoperative","TKA","2026-08-04",{"date":179,"type":34},"2026-08-07",{"date":181,"type":34},"2024-04-01",{"date":183,"type":22},"2026-08-31",{"name":185,"class":99},"Thammasat University Hospital",{"id":187,"slug":188,"hasResults":12,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":194,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":195,"targetDuration":197,"studyType":139,"phases":4,"briefSummary":198,"conditions":199,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":4},"100650700","15-hydroxyprostaglandin-dehydrogenase-in-osteoarthritis-and-ankylosing-spondylitis-100650700","NCT07751263","15-Hydroxyprostaglandin Dehydrogenase in Osteoarthritis and Ankylosing Spondylitis","15-Hydroxyprostaglandin Dehydrogenase in Osteoarthritis and Ankylosing Spondylitis: Associations With Clinical and Musculoskeletal Ultrasound Features.","HPGD-OA-AS-US","Inclusion Criteria:\n\n* Inclusion criteria\n\n  * Adults aged 18 years or older. AxSpA group Patients diagnosed as ankylosing spondylitis according to ASAS criteria . R OA group\n\n    * Adults with osteoarthritis Diagnosed according to the American College of Rheumatology classification criteria.\\[8\\]R ACR Clinical classification criteria for Osteoarthritis of the hip ACR Clinical classification criteria for Osteoarthritis of the knee ACR Clinical classification criteria for Osteoarthritis of the hand Control group Age- and sex-matched healthy controls.\n\nExclusion Criteria:\n\n* • Other inflammatory arthritides such as psoriatic arthritis, gout, or SLE-related arthritis.\n\n  * Septic arthritis or suspected joint infection.\n  * Recent intra-articular steroid injection if it may influence biomarker results.\n  * Any major systemic illness likely to affect biomarker measurement or ultrasound interpretation.\n  * Patients received certain drugs as non-steroidal anti-inflammatory drugs (NSAIDs)",true,{"count":196,"type":22},51,"1 Year","To evaluate serum and synovial fluid 15-PGDH levels in patients with osteoarthritis and ankylosing spondylitis and determine their associations with clinical and musculoskeletal ultrasound features.\n\nTo compare 15-PGDH concentrations among patients with knee osteoarthritis, and ankylosing spondylitis with knee effusion\n\nTo evaluate whether serum 15-PGDH reflects intra-articular 15-PGDH concentrations.\n\nAnalysis the level of 15-PGDH in relation to disease activity and severity of both diseases.",[28,200],"Ankylosing Spondylitis","2026-08-03",{"date":179,"type":34},{"date":204,"type":22},"2026-08-02",{"date":206,"type":22},"2028-08-02",{"name":208,"class":99},"Assiut University",{"id":210,"slug":211,"hasResults":12,"nctId":212,"briefTitle":213,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":12,"sex":18,"minAge":216,"maxAge":80,"enrollmentInfo":217,"targetDuration":4,"studyType":23,"phases":219,"briefSummary":220,"conditions":221,"keywords":223,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":128},"100604575","phonophoresis-with-bee-venom-evaluating-its-efficacy-in-managing-pain-and-enhancing-mobility-in-knee-osteoarthritis-patients-100604575","NCT07151300","Phonophoresis With Bee Venom: Evaluating Its Efficacy in Managing Pain and Enhancing Mobility in Knee Osteoarthritis Patients","BEE-KNEE","Inclusion Criteria:\n\n* Age 40-75 years\n* Clinically and radiographically confirmed knee osteoarthritis\n* Moderate to severe pain (VAS ≥ 4)\n* Willingness to provide informed consent\n\nExclusion Criteria:\n\n* Allergy to bee products or topical agents used in the study\n* Knee surgery or trauma in the past year\n* Intra-articular injection in the past 6 months\n* Other musculoskeletal or systemic conditions affecting the knees (e.g., rheumatoid arthritis)\n* Pregnancy or contraindication to ultrasound therapy","40 Years",{"count":218,"type":22},30,[84],"Brief Summary:\n\nThis single-blind, randomized controlled trial will investigate the efficacy of bee venom phonophoresis in managing pain and improving mobility in patients with knee osteoarthritis. Thirty adults aged 40-75 years with clinically and radiographically confirmed knee osteoarthritis will be randomly assigned to receive either bee venom phonophoresis or placebo phonophoresis with a neutral gel. Ultrasound parameters will be standardized for all participants.\n\nPrimary outcomes are pain reduction, measured by the Visual Analog Scale (VAS), and functional mobility, assessed by the Timed Up and Go (TUG) test. The secondary outcome is walking endurance, measured by the Six-Minute Walk Test (6MWT). Assessments will be conducted at baseline and post-intervention.\n\nThe study is designed to determine whether bee venom phonophoresis offers greater clinical benefit compared to placebo phonophoresis, potentially providing a non-invasive, adjunctive treatment option for knee osteoarthritis. Ethical approval has been obtained from the Faculty of Physical Therapy, Sinai University, and all participants will provide written informed consent.",[222,28],"Knee Osteoarthritis",[28,224],"Osteoarthritis, Knee","2026-08-01",{"date":177,"type":34},{"date":228,"type":22},"2026-08-15",{"date":230,"type":22},"2027-12-25",{"name":232,"class":99},"Sinai University",{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":12,"sex":18,"minAge":239,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":139,"phases":4,"briefSummary":242,"conditions":243,"keywords":247,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":257},"100602053","a-prospective-post-market-clinical-follow-up-study-of-the-incompass-total-ankle-system-100602053","NCT07118501","A Prospective, Post-Market, Clinical Follow-up Study of the Incompass™ Total Ankle System","Inclusion Criteria:\n\n1. The participant must be willing and able to sign a written approved informed consent form (ICF) approved by Institutional Review Board (IRB) or Ethics Committee (EC)\n2. Participants must be males or non-pregnant females aged 21 years or older at the time of surgery;\n3. Willing and able to comply with the requirements of the clinical investigation plan (CIP), including attend all required study visits.\n4. The participant must be able to follow instructions and deemed capable of completing clinical investigation questionnaires.\n5. Considered a candidate for total ankle replacement with the Incompass Total Ankle System in accordance with its legally approved Indication for Use (IFU).\n\nExclusion Criteria:\n\n1. Participant with an ankle condition, as determined by the investigator, to be an inappropriate candidate for total ankle replacement;\n2. Participant is currently enrolled in or plans to enroll in any concurrent drug and\u002For device clinical investigation that, in the opinion of the Investigator, may confound results;\n3. Any participant that meets the definition of a Vulnerable Subject per ISO 14155 Section 3.44.\n4. Participants who have participated previously in this clinical trial and who have been withdrawn.\n5. Participant who is, or will be, inaccessible for follow-up\n6. Participant is pregnant or intends to become pregnant during the course of the study.\n7. Participants with a medical or physical condition that, in the opinion of the Investigator, would preclude safe participation in the clinical investigation.\n8. Participants requiring revision total ankle replacement of the ankle being considered for the study;\n9. Participants with a failed previous ankle surgery (e.g., takedown fusion)\n10. Participants with any infection at the ankle site or infections at distant sites that could migrate to the ankle, including sepsis and osteomyelitis;\n11. Participants with compromised vascularity that would inhibit blood supply to the operative site;\n12. Neuropathic arthropathy of the joint;\n13. Insufficient bone stock or bone quality that cannot provide adequate support of the device;\n14. Participants who have documented or suspected sensitivity to the implant materials.\n15. Participants with inadequate neuromuscular status or those having poor skin coverage around the joint, which would make the procedure unjustifiable\n16. Participant who routinely place excessive loads on their ankle as caused by activity and\u002For patient weight, per investigator discretion; or\n17. Any mental or neuromuscular disorder that would create an unacceptable risk of failure or complications in postoperative care.","21 Years",{"count":241,"type":22},200,"The goal of this study is to demonstrate the safety and performance of the Incompass™ Total Ankle System after surgery over the standard follow-up period. The study will measure improvements in patient-reported information related to quality of life and pain following surgery. In order to do this, medical imaging (i.e. X-Rays, CT scans) which have been taken as part of routine care, will be reviewed. Any additional X-Rays conducted during the period of the research will also be reviewed.\n\nThe Incompass™ Total Ankle System has been cleared by the Food and Drug Administration (FDA). The products are already in use routinely in ankle replacement surgeries. No part of this study is experimental.",[244,28,245,246],"Post Traumatic Arthritis","Total Ankle Replacement","Total Ankle Prosthesis",[245],"2026-07-29",{"date":250,"type":34},"2026-07-30",{"date":252,"type":34},"2026-02-06",{"date":254,"type":22},"2038-09-01",{"name":256,"class":41},"Stryker Trauma and Extremities",5,{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":12,"sex":18,"minAge":216,"maxAge":265,"enrollmentInfo":266,"targetDuration":4,"studyType":23,"phases":268,"briefSummary":269,"conditions":270,"keywords":271,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":128},"100634243","genicular-artery-embolization-for-knee-osteoarthritis-100634243","NCT07537153","Genicular Artery Embolization for Knee Osteoarthritis","Genicular Artery Embolization for Patients With Mild-To-Moderate Knee Osteoarthritis","Inclusion Criteria:\n\n* Age 40-80 years\n* Mild-to-moderate knee OA as determined by radiographs demonstrating Kellgren- Lawrence grade 2-3\n* Self-reported pain of at least 5\u002F10 VAS questionnaire\n* Failure of conservative therapy, such as pain medications, for at least 3 months\n* Patient must understand and sign the informed consent\n* Patient can comply with the proposed follow-up schedule\n* Patient can follow the post-operative management\n\nExclusion Criteria:\n\n* History of rheumatoid arthritis\n* Renal insufficiency precluding angiography (GFR \\\u003C 50 mL\u002Fmin)\n* Irreversible coagulopathy\n* Previous knee arthroplasty on the intended knee\n* Existing knee joint infection\n* Kellgren-Lawrence grade 1 or 4\n* Severe atherosclerosis as manifest by claudication and\u002For diminished peripheral pulses\n* Life expectancy \\\u003C 6 months\n* Infectious arthritis\n* Allergy to iodinated contrast resulting in anaphylaxis\n* Pregnant or interested in becoming pregnant three months from the date of the GAE procedure\n* Involved in litigation or worker's compensation claims","80 Years",{"count":267,"type":22},15,[84],"Patients will be asked to take part in this research study because they have mild-to-moderate knee osteoarthritis (OA) and were referred clinically for a procedure called Genicular Artery Embolization (GAE). Osteoarthritis is the most common form of arthritis. It occurs when the protective cartilage that cushions the ends of the bones wears down over time. The symptoms of OA include pain or aching, stiffness, decreased range of motion, and swelling. The purpose of this study is to evaluate the safety and effectiveness of GAE for the treatment of knee pain attributed to OA.\n\nResearch participants will be in this research study for about 3 years. The study includes a screening visit, GAE procedure, and six follow-up visits.\n\nAt the screening visit, a review of their medical history, demographics, and medications will be collected; physical examination will be completed; knee x-ray will be done; and two questionnaires on your knee pain will be administered. The GAE procedure will involve receiving sedation or medication to help them relax, lidocaine injected under the skin in the area of the body where catheters will be inserted into one of your arteries and then using x-ray, a catheter will be directed to the arteries supplying the lining of the knee. Then tiny microspheres will be injected into the artery to decrease the blood supply to this knee joint tissue.\n\nThe follow-up visits up to 12 months will include a focused physical examination of the treated knee, documentation of medications, and two questionnaires will be administered. The follow-up visits at year 2 and 3 will include documentation of medications and any new treatments for OA as well as completion of two questionnaires. Follow-up visits maybe conducted in clinic or remotely.",[28,222],[28,222,272,273,274,275,276],"Genicular Artery Embolization","GAE","Embosphere Microspheres","GAE Knee","GAE Embosphere Microspheres","2026-07-11",{"date":279,"type":34},"2026-07-14",{"date":281,"type":34},"2026-07-10",{"date":283,"type":22},"2031-04-10",{"name":285,"class":99},"Northwestern University",{"id":287,"slug":288,"hasResults":12,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":12,"sex":18,"minAge":216,"maxAge":293,"enrollmentInfo":294,"targetDuration":4,"studyType":23,"phases":296,"briefSummary":297,"conditions":298,"keywords":299,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":128},"100645575","weighted-dangling-exercises-vs-vastus-medialis-oblique-muscle-neuromuscular-stimulation-for-knee-osteoarthritis-100645575","NCT07701174","Weighted Dangling Exercises vs Vastus Medialis Oblique Muscle Neuromuscular Stimulation for Knee Osteoarthritis","Effectiveness of Weighted Dangling Exercises Versus Vastus Medialis Oblique Muscle Neuromuscular Stimulation in Patients With Knee Osteoarthritis","Inclusion Criteria:\n\nBoth genders and aged between 40 and 60 years. Symptoms of unilateral knee pain and crepitus persist for at least 6 months during ascending and descending motion. Radiographic KOA; grade 2 or more according to Kellgren and Lawrence scale. Patient referred by an orthopedic physician Those who have taken oral corticosteroids within the last month or who received intra-articular corticosteroid injection or analgesic injection intervention for hip or knee pain within the last 3 month\n\nExclusion Criteria:\n\n* Recent surgery (within three months) history of hip or knee joint replacement, tibial osteotomy, orthoses with systemic arthritis, history of trauma such as knee fracture and other with muscular disease of neurological disorders that would affect lower extremity function is excluded.","60 Years",{"count":295,"type":22},48,[84],"This randomized controlled trial aims to compare the effectiveness Weighted dangling exercises versus vastus medialis oblique muscle neuromuscular electrical stimulation(VMO+NMES) in patients with knee osteoarthritis. The study will recruit 48 participants (accounting for 10% attrition), aged 40-60 years, from University of Lahore Teaching Hospital using convenience sampling. Participants will be randomly allocated into two groups: an interventional group receiving WDE and other interventional group undergoing VMO strength training with NMES. Both interventions will be administered three times per week for 8 weeks under professional supervision. Outcome measures including pain intensity (NPRS), Functional Disability (Western Ontario and McMaster Universities Osteoarthritis Index),Muscle Strength (MMT) will be assessed at baseline, 4 weeks, and 8 weeks. Data will be analyzed using SPSS, with appropriate parametric or non-parametric tests applied after checking data normality. Ethical approval will be obtained, informed consent will be secured, and participant confidentiality will be strictly maintained.",[28],[222],"2026-07-08",{"date":279,"type":34},{"date":303,"type":34},"2026-05-25",{"date":305,"type":22},"2026-09-10",{"name":307,"class":99},"University of Lahore",{"id":309,"slug":310,"hasResults":12,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":4,"eligibilityCriteria":314,"healthyVolunteers":12,"sex":18,"minAge":239,"maxAge":4,"enrollmentInfo":315,"targetDuration":4,"studyType":23,"phases":317,"briefSummary":318,"conditions":319,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":257},"100564627","emphasys-cup-positioning-in-tha-with-non-invasive-navigation-velys-hip-navigation-vhn-100564627","NCT06631638","EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN))","Planned vs. Actual Acetabular Cup Position in Total Hip Arthroplasty With Non-Invasive Navigation","Inclusion Criteria:\n\n1. All hip replacement component devices are to be used according to the approved indications.\n2. The subject is undergoing a standard of care primary uncemented hip replacement with the EMPHASYS cup and a CORAIL, EMPHASYS or ACTIS stem via the posterolateral, anterolateral, or direct lateral approach with the subject in the lateral decubitus position.\n3. The subject is a candidate for implantation utilizing the VELYS Hip Navigation system with CUPTIMIZE advanced\n4. Individuals who are able to speak, read, and comprehend the Informed Participant Consent Document and willing and able to provide consent for participation in the study and have authorized the transfer of his\u002Fher information to DePuy Synthes.\n5. Individuals who are willing and able to complete follow-up as specified by the study protocol.\n6. Individuals who are willing and able to complete the Subject Hip Outcomes questionnaires (i.e., FJS-12, EQ-5D-5L and Hip Evaluation) as specified by the study protocol.\n7. Individuals who are not bedridden per the discretion of the investigator.\n8. Individuals who are a minimum age of 21 years at the time of consent\n\nExclusion Criteria:\n\n1. Active local or systemic infection.\n2. Loss of musculature, neuromuscular compromise or vascular deficiency in the affected limb rendering the procedure unjustified.\n3. Poor bone quality, such as osteoporosis, where, in the surgeon's opinion, there could be considerable migration of the prosthesis or a significant chance of fracture of the femoral shaft and\u002For the lack of adequate bone to support the implant(s).\n4. Charcot's or Paget's disease.\n5. The Subject is a woman who is pregnant or lactating.\n6. Subject had a contralateral amputation.\n7. Previous partial hip replacement in affected hip.\n8. Subject has participated in a clinical investigation with an investigational product (drug or device) in the last three months.\n9. Contralateral hip was replaced less than 6 months prior to surgery date.\n10. Subject is currently involved in any personal injury litigation, medical-legal or worker's compensation claims.\n11. Subject was diagnosed and is taking prescription medications to treat a muscular disorder that limits mobility due to severe stiffness and pain such as fibromyalgia or polymyalgia.\n12. Subject has a medical condition with less than 2 years of life expectancy.\n13. Subject, in the opinion of the Investigator, is a drug or alcohol abuser or has a psychological disorder that could affect their ability to complete subject reported questionnaires or be compliant with follow-up requirements.",{"count":316,"type":22},118,[84],"The purpose of this research is to gather clinical and radiographic (X-ray) information about EMPHASYS™ acetabular shell (also called a hip 'cup') placement in total hip replacement surgery using a non-invasive surgical navigation system called VELYS™ hip navigation system with CUPTIMIZE™ Advanced Hip-Spine Analysis software.\n\nData collected in this study will be compared with data collected from implantations using different cup positioning instrumentation and techniques to assess performance.",[28,320,321,322,323,324],"Traumatic Arthritis","Rheumatoid Arthritis","Congential Hip Dysplasia","Avascular Necrosis of the Femoral Head","Certain Cases of Ankylosis","2026-07-02",{"date":327,"type":34},"2026-07-06",{"date":329,"type":34},"2025-10-24",{"date":331,"type":22},"2027-12-31",{"name":333,"class":41},"DePuy Orthopaedics",{"id":335,"slug":336,"hasResults":12,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":4,"eligibilityCriteria":340,"healthyVolunteers":12,"sex":18,"minAge":216,"maxAge":4,"enrollmentInfo":341,"targetDuration":4,"studyType":139,"phases":4,"briefSummary":343,"conditions":344,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":128},"100484867","thromboxane-a2-and-osteoarthritis-100484867","NCT05593640","Thromboxane A2 and Osteoarthritis","Throboxane Effect on Chondrocytes; Role in Osteoarthritis","Inclusion Criteria:\n\n* presence of knee osteoarthritis with effusion, , no inflammatory disease\n\nExclusion Criteria:\n\n* anticoagulant treatment\n* inflammatory disease",{"count":342,"type":22},20,"TXA2 inhibits the expression of the primary marker of thermogenesis (UCP1) while prostacyclin (PGI2), another metabolite derived from arachidonic acid, enhances its expression. Given the close relationship between the adipocyte and the chondrocyte, the study team hypothesises that thromboxane A2 controls chondrocyte formation and function and thus cartilage homeostasis. The study objectives are: i) to analyse the role of TXA2 on chondrocyte differentiation in vitro, ii) to determine the association between circulating and tissue TXA2 levels in a rat model of osteoarthritis, and iii) to correlate circulating and synovial fluid levels of TXA2 with the development of osteoarthritis in a small human cohort. The proposed research aims to better understand the mechanisms underlying the role of lipid metabolites in chondrocyte formation and function, paving the way for the development of nutritional and pharmacological therapies to combat OA and associated metabolic disorders.",[28],"2026-06-25",{"date":347,"type":34},"2026-06-29",{"date":349,"type":34},"2022-09-01",{"date":351,"type":22},"2027-06-25",{"name":353,"class":99},"Centre Hospitalier Universitaire de Nice",{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":358,"acronym":359,"eligibilityCriteria":360,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":361,"targetDuration":4,"studyType":23,"phases":362,"briefSummary":363,"conditions":364,"keywords":365,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":377},"100629341","synovial-tissue-as-a-biomarker-in-the-early-management-of-osteoarthritis-100629341","NCT07473414","Synovial Tissue as a Biomarker in the Early Management of Osteoarthritis","SYNPA","Inclusion Criteria:\n\n* Diagnosis of early osteoarthritis defined by the following clinical criteria:\n\n  1. score ≤ 85% in at least two of the four categories of the KOOS questionnaire: pain, symptoms\u002Fsigns, function and quality of life;\n  2. presence of tenderness on palpation of the joint space or crepitus (clinical examination);\n  3. Kellgren and Lawrence (KL) score of 0 or 3 (X-rays).\n* Referred for therapeutic management including an intra-articular injection in the affected knee\n* Patient affiliated with a social security scheme\n* Patient able to understand the protocol and having signed an informed consent form.\n\nExclusion Criteria:\n\n* Minors\n* Adults under guardianship or trusteeship\n* Pregnant women\n* Breastfeeding women\n* Protected patients\n* Curative anticoagulation\n* Thrombocytopenia \\\u003C 50,000 platelets\u002Fmm3\n* Patients who object to participating in the study.",{"count":218,"type":22},[84],"Osteoarthritis is a common disease whose prevalence continues to increase. To date, there is no medical treatment that has proven effective, and only symptomatic treatments exist, mainly to reduce pain.\n\nArthroplasty, a costly and invasive surgical procedure, is often unavoidable in advanced stages of the disease. More than just a degenerative disease of the cartilage, osteoarthritis is now recognised as a heterogeneous disease causing multi-tissue damage of varying intensity. Synovitis plays a particularly important role in the onset and progression of osteoarthritis and has been closely correlated with radiographic severity, pain and loss of joint function. The investigators have identified several synovial histological pathotypes based on the type of synovial cell infiltrate and its distribution in samples from advanced osteoarthritis (surgical waste from prosthesis implantation). The investiogators' studies show that the presence of these pathotypes appears to be related to the clinical phenotype of patients. Analysis of synovial tissue at earlier stages of the disease is now essential to advance the understanding of the role of synovitis in osteoarthritis and its link to the clinical phenotype of patients.\n\nThe objective of this protocol is to describe the different synovial histological pathotypes present in the early stages of osteoarthritis; To this end, the investigators will establish a cohort of osteoarthritis patients with a collection of synovial tissue samples obtained by ultrasound-guided needle biopsy in an outpatient setting, a well-tolerated procedure with simple follow-up, as well as blood sampling.",[28],[366,367,368],"arthroplasty","synovial tissue","synovial histological pathotypes","2026-06-23",{"date":345,"type":34},{"date":372,"type":34},"2026-05-26",{"date":374,"type":22},"2028-05-26",{"name":376,"class":99},"Nantes University Hospital",2,{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":384,"eligibilityCriteria":385,"healthyVolunteers":12,"sex":18,"minAge":216,"maxAge":293,"enrollmentInfo":386,"targetDuration":4,"studyType":139,"phases":4,"briefSummary":388,"conditions":389,"keywords":390,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":128},"100638384","blood-cell-ratios-as-predictors-of-response-to-platelet-rich-plasma-in-knee-osteoarthritis-100638384","NCT07617233","Blood Cell Ratios as Predictors of Response to Platelet-Rich Plasma in Knee Osteoarthritis","Baseline Neutrophil-to-Lymphocyte Ratio and Related Complete Blood Count-Derived Inflammatory Indices as Predictors of Clinical Response to Intra-Articular Platelet-Rich Plasma in Knee Osteoarthritis: A Prospective Single-Arm Cohort Study","PRP-NLR","Inclusion Criteria:\n\n* Age 40 to 60 years\n* Symptomatic primary knee osteoarthritis, Kellgren-Lawrence grade 2 or 3 on weight-bearing radiographs\n* Body mass index below 40\n* Candidate for and scheduled to receive a course of intra-articular platelet-rich plasma for the index knee\n* Able and willing to provide written informed consent and to attend the 6-month follow-up schedule\n\nExclusion Criteria:\n\n* Systemic inflammatory or autoimmune disease\n* Active acute infection at the time of enrollment\n* Current anticoagulant or antiplatelet therapy, or current or recent chemotherapy\n* Any contraindication to platelet-rich plasma per the 2025 GRIIP recommendations\n* Intra-articular injection of the index knee within the previous 6 months\n* Inability to comply with the planned follow-up schedule",{"count":387,"type":22},120,"Intra-articular platelet-rich plasma (PRP) injection is a widely used treatment for knee osteoarthritis, but patients respond to it very differently and there is currently no simple, inexpensive way to predict who will benefit. The neutrophil-to-lymphocyte ratio (NLR) and related indices derived from a routine complete blood count reflect a person's baseline inflammatory state. This prospective single-arm observational cohort study investigates whether the baseline NLR, together with the platelet-to-lymphocyte ratio (PLR), the systemic immune-inflammation index (SII), and the monocyte-to-lymphocyte ratio (MLR), predicts the clinical response to intra-articular PRP in patients with Kellgren-Lawrence grade 2 to 3 knee osteoarthritis. The investigators will enroll 120 patients aged 40 to 60 years, each of whom receives a standardized course of three leukocyte-poor PRP injections one week apart. Patients are followed for 6 months, and the primary clinical outcome is the change in the WOMAC osteoarthritis index at 6 months. Outcome assessors are blinded to patients' blood-count values. If a baseline blood ratio predicts response, it could become a low-cost tool to guide patient selection for PRP.",[222,28],[391,392,393,394,395,396,397,398,399,400,401],"platelet-rich plasma","PRP","knee osteoarthritis","neutrophil-to-lymphocyte ratio","NLR","systemic immune-inflammation index","biomarker","predictor","intra-articular injection","WOMAC","inflammatory index","2026-06-18",{"date":369,"type":34},{"date":405,"type":22},"2026-09",{"date":407,"type":22},"2027-07",{"name":409,"class":99},"Utku Gürhan",{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":416,"eligibilityCriteria":417,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":418,"targetDuration":420,"studyType":139,"phases":4,"briefSummary":421,"conditions":422,"keywords":424,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":431,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":128},"100581477","heidelberg-registry-for-hip-and-knee-joint-implants-and-revisions-100581477","NCT06850818","Heidelberg Registry for Hip and Knee Joint Implants and Revisions","Endoprosthesis Registry Heidelberg (EPR-HD): Registry for the Analysis of Patients Following Primary Implantation or Revision Surgery of Artificial Joints in Hip and Knee Joint Pathologies","EPR-HD","Inclusion Criteria:\n\n* All patients undergoing hip or knee arthroplasty at our institution\n* All patients undergoing revision surgery following hip oder knee arthroplasty\n\nExclusion Criteria:\n\n* Lack of prospective consent for study participation\n* Lack of capacity to provide informed consent\n* Minor status (underage)",{"count":419,"type":22},10000,"20 Years","The Endoprosthesis Registry Heidelberg (EPR-HD) is a clinical registry designed to systematically collect and analyze data from patients undergoing primary implantation or revision surgery of artificial hip and knee joints. The main objective of the registry is to evaluate long-term outcomes, complication rates, implant survival, and functional results associated with joint replacement procedures in patients with various hip and knee joint pathologies.\n\nBy gathering comprehensive clinical data, EPR-HD aims to improve the understanding of patient outcomes after endoprosthetic procedures, identify potential factors influencing implant success, and support evidence-based improvements in surgical techniques and patient care. The registry includes adult patients treated at Heidelberg University Hospital, with data collected at multiple time points during routine clinical follow-up. This registry will contribute to the optimization of joint replacement strategies and promote high-quality patient care.",[28,423],"Arthroplasty",[425,423,426,28,427,428,429],"Endoprostheses","Joint Replacement","Registry","Knee","Hip","2026-06-10",{"date":432,"type":34},"2026-06-11",{"date":434,"type":34},"2007-01-01",{"date":436,"type":22},"2035-12",{"name":438,"class":99},"University Hospital Heidelberg",{"id":440,"slug":441,"hasResults":12,"nctId":442,"briefTitle":443,"officialTitle":444,"acronym":445,"eligibilityCriteria":446,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":265,"enrollmentInfo":447,"targetDuration":4,"studyType":23,"phases":448,"briefSummary":449,"conditions":450,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":453,"completionDateStruct":455,"leadSponsor":457,"locationsCount":128},"100642884","phase-4-plasma-concentrations-of-intraosseous-versus-intravenous-tranexamic-acid-in-joint-arthroplasty-100642884","NCT07614087","Plasma Concentrations of Intraosseous Versus Intravenous Tranexamic Acid in Joint Arthroplasty","A Prospective Randomized Controlled Trial Comparing Plasma Concentrations of Intraosseous and Intravenous Tranexamic Acid in Patients Undergoing Joint Arthroplasty","IO TXA","Inclusion Criteria:\n\n* Age between 18 and 80 years\n* Patients scheduled for primary total hip arthroplasty or total knee arthroplasty\n* Diagnosis of osteoarthritis\n* American Society of Anesthesiologists (ASA) physical status I-III\n* Preoperative hemoglobin ≥ 9 g\u002FdL\n* Ability to provide written informed consent\n* Willingness to comply with postoperative follow up and study procedures\n\nExclusion Criteria:\n\n* History of coagulation disorders or bleeding disorders\n* History of pulmonary embolism\n* Known allergy to tranexamic acid\n* Pregnancy or breastfeeding\n* Severe hepatic or renal dysfunction\n* Preoperative anticoagulant therapy\n* Body mass index \\> 40 kg\u002Fm²\n* Body weight \\\u003C 45 kg",{"count":166,"type":22},[109],"This prospective randomized controlled trial aims to compare the pharmacokinetic profiles of intraosseous and intravenous tranexamic acid administration in patients undergoing primary total joint arthroplasty. Eligible patients undergoing total hip or total knee arthroplasty will be randomly assigned to receive tranexamic acid either through intraosseous injection or intravenous injection at a dose of 15 mg\u002Fkg. Blood samples will be collected at predefined time points to evaluate plasma concentrations and pharmacokinetic characteristics of tranexamic acid. Secondary outcomes include coagulation function, intraoperative blood loss, transfusion rate, and hemoglobin changes. The study aims to provide evidence regarding the pharmacokinetic characteristics and clinical feasibility of intraosseous tranexamic acid administration in joint arthroplasty.",[28],"2026-06-09",{"date":432,"type":34},{"date":454,"type":22},"2026-05-27",{"date":456,"type":22},"2026-12-30",{"name":458,"class":99},"Hua Luo",{"id":460,"slug":461,"hasResults":12,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":4,"eligibilityCriteria":465,"healthyVolunteers":194,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":466,"targetDuration":4,"studyType":139,"phases":4,"briefSummary":468,"conditions":469,"keywords":470,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":474,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":128},"100528988","developing-allogeneic-musculoskeletal-therapies-100528988","NCT06167928","Developing Allogeneic Musculoskeletal Therapies","Investigating the Potential for Musculoskeletal Tissues and Cells Isolated From Juvenile Patients in the Development of Novel Therapies for Cartilage and Bone Injury and Osteoarthritis","Inclusion Criteria:\n\nFor juvenile\u002Finfant donors:\n\n* Parents\u002Fguardians being able to provide signed and dated informed consent form.\n* Scheduled for one of the following surgical treatments:\n\nDigit amputations due to polydactyly. Surgery to treat dislocated hips.\n\nFor biobank\u002FNHSBT donors\n\n* Informed consent via consenting institution.\n\nExclusion Criteria:\n\n* Parents\u002Fguardians not understanding the Patient Information Sheet",{"count":467,"type":22},325,"The goal of this observational study is to analyse the cartilage and bone forming potential of cells isolated from the tissues of patients undergoing surgery for the treatment of polydactyly, hip dislocation and from other bio-banked cartilage tissues. The main question it aims to answer is:\n\nWhich of the following tissues from polydactyly digit, iliac apophysis or other bio-banked cartilage produce better cartilage in vitro and in vivo? Participants receiving digit amputation surgery for treatment of polydactyly will be asked to donate the associated waste tissue whilst participants receiving surgery to treat a dislocated hip will be asked to donate an extra small piece of cartilage tissue (approximately 1 gram) from the iliac apophysis. Other tissues for the study will be obtained from those donated to biobanks.",[28],[471,472,473],"Cell therapy","Musculoskeletal","Allogeneic",{"date":432,"type":34},{"date":476,"type":34},"2018-10-08",{"date":478,"type":22},"2037-09-01",{"name":480,"class":99},"Keele University",{"id":482,"slug":483,"hasResults":12,"nctId":484,"briefTitle":485,"officialTitle":486,"acronym":4,"eligibilityCriteria":487,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":488,"targetDuration":4,"studyType":23,"phases":490,"briefSummary":491,"conditions":492,"keywords":495,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":500,"startDateStruct":502,"completionDateStruct":504,"leadSponsor":506,"locationsCount":128},"100640961","phase-4-post-op-prednisone-and-glucose-monitoring-in-tka-100640961","NCT07630896","Post-op Prednisone and Glucose Monitoring in TKA","Postoperative Prednisone Regimen in TKA and Its Effect on Continuous Glucose Levels","Inclusion Criteria:\n\n* Undergoing Primary Unicompartmental Knee Arthroplasty or Total Hip Arthroplasty\n* Age 18 and above\n\nExclusion Criteria:\n\n* Steroid therapy\n* Narcotic use within past 3 months\n* History of corticosteroid intolerance\n* Pregnancy\n* Uncontrolled diabetes\n* Doesn't own smart phone\n\nDrop Criteria:\n\n\\- 2nd dose of IV dexamethasone",{"count":489,"type":22},104,[109],"This study compares the efficacy of a 5-day post-operative oral prednisone regimen (40 mg daily) with the standard intraoperative steroid regimen, focusing on pain, swelling, range of motion, opioid use, and glucose levels monitored continuously.",[28,493,494],"Unicompartmental Knee Arthroplasty","Total Hip Arthroplasty (THA)",[496,497,498],"Post-operative pain","Prednisone","Continuous Glucose Monitoring","2026-06-03",{"date":501,"type":34},"2026-06-05",{"date":503,"type":22},"2026-07-01",{"date":505,"type":22},"2028-03",{"name":507,"class":99},"Columbia University",{"id":509,"slug":510,"hasResults":12,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":514,"eligibilityCriteria":515,"healthyVolunteers":12,"sex":18,"minAge":163,"maxAge":516,"enrollmentInfo":517,"targetDuration":4,"studyType":23,"phases":518,"briefSummary":519,"conditions":520,"keywords":525,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":540,"locationsCount":128},"100555487","the-proactive-study-for-black-elders-100555487","NCT06512727","The PROACTIVE Study for Black Elders","Testing the Pain Relief of musculOskeletal Conditions and Arthritis Using Carefully Tailored InterVEntions (PROACTIVE) Intervention: A Randomized Controlled Trial","PROACTIVE","Inclusion Criteria:\n\n1. Self-identify as being part of the Black American diaspora (Black\u002FAfrican American, Afro-Caribbean)\n2. Age 50-92 years\n3. Self-report chronic musculoskeletal pain (CMP) as defined as persistent or recurrent pain lasting 6 months or longer that arises as part of a disease or injurious process directly affecting bone(s), joint(s), muscle(s), or related soft tissue(s)\n4. Self-report a chronic musculoskeletal condition (e.g., osteoarthritis, chronic low back pain) in at least one lower extremity joint (hip, knee, low back, or ankle pain)\n5. Report chronic musculoskeletal symptoms: aching, stiffness, or swelling in a major lower extremity joint or low back on most days (4-5\u002F7) of the week\n6. Have (or be eligible for) a healthcare insurance plan in the state of Florida (Medicare, Medicaid, Medicare Advantage plans, Blue Cross\u002FBlue Shield, Humana, Aetna, etc.)\n7. Able to read, write, and understand English at sixth-grade level\n\nExclusion Criteria:\n\n1. Unwilling to be randomized to either study arm\n2. Self-reported diagnosis of sickle cell disease or related thalassemias\n3. History of major neurological event (e.g., stroke) or current neurological disease (e.g., Parkinson's disease, multiple sclerosis, epilepsy)\n4. Major cardiovascular problem in the past 6 months that would cause shortness of breath and\u002For chest pain (e.g. myocardial infarction, coronary artery bypass graft, or valve replacement, pulmonary embolism or deep venous thrombosis) or uncontrolled Hypertension (Systolic Blood Pressure (SBP) \\> 170 mmHg, Diastolic Blood Pressure (DBP) \\> 90 mmHg) OR Hypotension (SBP \\\u003C90 mmHg, DBP \\\u003C60 mmHg)\n5. Currently undergoing curative or palliative chemotherapy or radiation for active cancer\n6. Severe physical impairment (e.g., a major activity of daily living disability requiring use of wheelchair as primary method of mobility, or unable to dress, bath, use the toilet, or transfer independently)\n7. Serious mental health disorder requiring hospitalization within past 12 months\n8. Severe sensory deficit (severe hearing loss or blindness)","92 Years",{"count":387,"type":22},[84],"Chronic musculoskeletal pain (CMP), while a leading cause of physical disablement, is a neglected national health disparity issue in Black communities. The purpose of this study is to test a novel culturally congruent pain self-management intervention. A total of 120 persons aged 50-92, self-identifying as Black or African American having CMP will be invited to participate in this study. The primary outcome measured throughout this 3-year study is movement-evoked pain (MEP).",[521,522,28,523,524],"Musculoskeletal Pain","Chronic Pain","Pain, Chronic","Movement Evoked Pain",[526,527,528,529,530,531,532],"chronic musculoskeletal pain","chronic pain","Black","African Americans","pain self-management","prayer","social determinants of health","2026-06-02",{"date":535,"type":34},"2026-06-04",{"date":537,"type":34},"2025-05-07",{"date":539,"type":22},"2027-10-01",{"name":541,"class":99},"University of Florida",{"id":543,"slug":544,"hasResults":12,"nctId":545,"briefTitle":546,"officialTitle":546,"acronym":4,"eligibilityCriteria":547,"healthyVolunteers":194,"sex":18,"minAge":548,"maxAge":293,"enrollmentInfo":549,"targetDuration":551,"studyType":139,"phases":4,"briefSummary":552,"conditions":553,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":559,"startDateStruct":561,"completionDateStruct":563,"leadSponsor":565,"locationsCount":128},"100637723","ai-based-phenome-data-analysis-for-predicting-the-onset-of-major-diseases-100637723","NCT07595718","AI-Based Phenome Data Analysis for Predicting the Onset of Major Diseases","Inclusion Criteria:\n\n1. Adults aged 30 to 60 years.\n2. Disease group: Participants with a confirmed diagnosis of at least one of the following conditions: type 2 diabetes mellitus, breast cancer, cardiovascular disease, osteoarthritis, or low back pain.\n3. Healthy control group: Participants with no prior diagnosis of type 2 diabetes mellitus, breast cancer, cardiovascular disease, osteoarthritis, or low back pain.\n4. No history or current diagnosis of major medical conditions that may affect study outcomes, including but not limited to chronic kidney disease or liver cirrhosis.\n5. Ability to understand the study procedures and provision of written informed consent prior to participation.\n\nExclusion Criteria:\n\n1. Participants with incomplete or insufficient clinical or health screening data.\n2. Participants considered inappropriate for study participation by the investigator.","30 Years",{"count":550,"type":22},1000,"1 Week","This study aims to develop and validate an artificial intelligence (AI)-based predictive model to estimate the risk of incident onset of five major diseases or conditions: cardiovascular disease, type 2 diabetes mellitus, breast cancer, low back pain, and osteoarthritis, in adults aged 30 to 60 years.\n\nFor each participant, an index date will be defined as the date of a prior health screening or another protocol-defined baseline clinical date. Incident disease status for each target disease or condition will be ascertained by retrospective review of electronic medical records for up to 10 years after the index date.\n\nThe study integrates retrospective clinical, health screening, laboratory, imaging, and electronic medical record data with prospectively collected biospecimen, proteomic, genomic, questionnaire, lifestyle, and digital health data. Prospective study procedures will be completed over approximately 1 week, with up to 2 additional weeks if needed.\n\nBy combining multimodal data, this study seeks to improve disease risk prediction and to identify clinical and biological factors associated with disease onset, ultimately supporting personalized risk stratification and preventive healthcare strategies.",[554,555,556,28,557],"Diabetes Mellitus Type 2","Breast Neoplasms","Low Back Pain","Cardiovascular Diseases","2026-05-12",{"date":560,"type":34},"2026-05-19",{"date":562,"type":34},"2026-04-02",{"date":564,"type":22},"2026-12-31",{"name":566,"class":99},"Jae Yong Jeon, MD",{"id":568,"slug":569,"hasResults":12,"nctId":570,"briefTitle":571,"officialTitle":572,"acronym":573,"eligibilityCriteria":574,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":575,"targetDuration":4,"studyType":23,"phases":577,"briefSummary":578,"conditions":579,"keywords":580,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":128},"100639531","total-knee-arthroplasty-with-personalized-implantation-computer-navigation-assisted-surgery-versus-robotic-assisted-surgery-100639531","NCT07574762","Total Knee Arthroplasty With Personalized Implantation: Computer Navigation-Assisted Surgery Versus Robotic-Assisted Surgery","Total Knee Replacement With Personalized Implantation Navigation-assisted Surgery Versus Robotic Assistance \"CAN-ARD\"","CAN-ARD","Inclusion Criteria:\n\n* Patient providing written informed consent according to regulatory requirements\n* Male or female patients aged ≥18 years\n* Patients undergoing primary total knee arthroplasty for osteoarthritis\n* Use of Attune® prosthesis with posterior cruciate ligament retention (CR) and patellar resurfacing\n\nExclusion Criteria:\n\n* History of ligament reconstruction\n* Previous fracture or bone surgery (osteotomy) of the ipsilateral femur or tibia (except hip or ankle surgery)\n* Preoperative knee stiffness with flexion contracture \\>15° or flexion \\\u003C90°\n* Individuals deprived of liberty by judicial or administrative decision\n* Patients not affiliated with a social security system\n* Patients unable to understand French\n* Patients with cognitive impairment\n* Patients whose place of residence makes close clinical follow-up impossible -- Women of childbearing potential without effective contraception\n* Pregnant or breastfeeding women",{"count":576,"type":22},140,[84],"Title: Personalized Total Knee Arthroplasty: Computer-Assisted Navigation vs. Robotic Assistance (CAN-ARD).\n\nSummary:\n\nKnee osteoarthritis is frequently treated with Total Knee Arthroplasty (TKA). However, approximately 20% of patients remain dissatisfied following the procedure. This study aims to compare two surgical assistance technologies designed to improve prosthetic placement accuracy: Computer-Assisted Navigation (CAN) and Robotic-Arm Assistance (RA).\n\nThe primary objective is to determine if there is a significant difference in functional outcomes and the \"forgotten joint\" sensation (measured by the Forgotten Joint Score - FJS) between patients operated on with robotic assistance versus those with traditional navigation at 3, 12, and 24 months post-surgery. The study's hypothesis is that there is no major clinical difference between these two techniques when applied within a personalized alignment strategy.",[28],[581,582,423,28],"Robotic","Navigation","2026-05-05",{"date":585,"type":34},"2026-05-08",{"date":587,"type":34},"2026-01-26",{"date":589,"type":22},"2029-01-26",{"name":591,"class":99},"Groupe Hospitalier Diaconesses Croix Saint-Simon",{"id":593,"slug":594,"hasResults":12,"nctId":595,"briefTitle":596,"officialTitle":597,"acronym":598,"eligibilityCriteria":599,"healthyVolunteers":12,"sex":18,"minAge":216,"maxAge":4,"enrollmentInfo":600,"targetDuration":4,"studyType":23,"phases":601,"briefSummary":604,"conditions":605,"keywords":606,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":611,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":616,"locationsCount":128},"100563041","phase-1-evaluation-of-the-safety-of-lipiodol-embolization-in-symptomatic-digital-osteoarthritis-refractory-to-conventional-treatment-100563041","NCT06611007","Evaluation of the Safety of LipiodolⓇ Embolization in Symptomatic Digital Osteoarthritis Refractory to Conventional Treatment","Evaluation of the Safety of LipiodolⓇ Embolization in Symptomatic Digital Osteoarthritis Refractory to Conventional Treatment: a Pilot Study of 15 Patients","EMBARDI","Inclusion Criteria:\n\n* Patients aged ≥ 40 years.\n* Osteoarthritis of the hand according to American College of Rheumatology criteria 1990\n* Osteoarthritis affecting at least two proximal and\u002For distal interphalangeal joints with a radiological Kellgren-Lawrence stage ≥ 2.\n* Symptomatic osteoarthritis within the last 3 months.\n* Visual analogue pain scale of the hand to be treated ≥ 40\u002F100 mm (most painful hand).\n* Inadequate response, adverse effects and\u002For contraindication to NSAIDs and non-opioid analgesics.\n* Patient affiliated to french social security or a similar health assurance.\n\nExclusion Criteria:\n\n* History of allergy to iodinated contrast media, LipiodolⓇ or poppies.\n* Vasomotor disorders (Raynaud\\'s syndrome, scleroderma, acrocyanosis).\n* Stenosis (\\>50%) or known atheromatous arterial occlusion of the upper limbs.\n* Obliterative arterial disease of the lower limbs at the critical ischaemia stage.\n* Severe to end-stage chronic renal insufficiency (glomerular filtration rate \\< 30ml\u002Fmin\u002F1.73m2), dialysis or renal transplant.\n* Arteritis such as thromboangiitis obliterans disease or other diseases\n* Previous thrombosis\u002Fdissection of the radial artery.\n* Chronic inflammatory rheumatic disease (rheumatoid arthritis, psoriatic arthritis, microcrystalline arthritis, etc.).\n* Known hyperthyroidism or large multinodular goiter.\n* Traumatic lesions, haemorrhages or chronic bleeding in the hand (not completely resolved within 3 months of the start of the lesion) requiring embolisation.\n* Pregnant or breast-feeding.\n* Patients covered by articles L1121-5 to L1121-8 of the French Public Health Code and\u002For who do not speak French.\n* Patients in a period of exclusion or in the course of another interventional clinical trial.",{"count":267,"type":22},[602,603],"PHASE1","PHASE2","The goal of this clinical trial is to evaluate the safety of arterial embolization using Lipiodol® in patients with symptomatic hand osteoarthritis refractory to conventional treatment. It will also learn about the efficacy of arterial embolization with Lipiodol® in reducing pain and improving hand function.\n\nThe main questions it aims to answer are:\n\n* What are the side effects and complications associated with the Lipiodol® arterial embolization procedure?\n* Does arterial embolization reduce pain intensity and improve hand function?\n\nResearchers will evaluate patients over a 6-month period to assess the safety of Lipiodol® embolization and its impact on joint pain, swelling, and functional capacity. Participants will:\n\n* Undergo arterial embolization with Lipiodol®\n* Participate in regular follow-ups to monitor pain relief, hand function, and any side effects\n* Have imaging studies to assess changes in joint vascularisation and damage",[28],[607,608,609],"Therapeutic embolization","Safety","Hand osteoarthritis","2026-05-04",{"date":583,"type":34},{"date":613,"type":34},"2025-01-30",{"date":615,"type":22},"2028-07-15",{"name":617,"class":99},"University Hospital, Grenoble",{"id":619,"slug":620,"hasResults":12,"nctId":621,"briefTitle":622,"officialTitle":622,"acronym":623,"eligibilityCriteria":624,"healthyVolunteers":12,"sex":18,"minAge":625,"maxAge":80,"enrollmentInfo":626,"targetDuration":4,"studyType":23,"phases":628,"briefSummary":629,"conditions":630,"keywords":635,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":638,"lastUpdatePostDateStruct":639,"startDateStruct":640,"completionDateStruct":642,"leadSponsor":644,"locationsCount":128},"100625073","ketogenic-diet-to-reduce-osteoarthritis-pain-in-mci-100625073","NCT07417891","Ketogenic Diet to Reduce Osteoarthritis Pain in MCI","KDROP-MCI","Inclusion Criteria:\n\n* English speaking\n* Diagnosis of major joint osteoarthritis\n* Diagnosis of mild cognitive impairment\n\nExclusion Criteria:\n\n* Diabetes that requires insulin\n* Cancer requiring chemo- or radiation therapy in the last 2 years\n* Cardiac event within 1 year\n* Recent history of renal stones\n* Diagnosis of fibromyalgia\n* Already following a ketogenic diet\n* Following a dietary pattern that does not allow for a ketogenic approach\n* Unable to control one's diet","55 Years",{"count":627,"type":22},10,[84],"Osteoarthritis and mild cognitive impairment are common conditions that share underlying biological processes related to metabolism and inflammation. This study will examine whether a well-formulated ketogenic diet influences pain, physical function, and cognitive outcomes in adults with osteoarthritis and mild cognitive impairment. Participants will follow a supervised ketogenic dietary intervention, with assessments conducted before and after the intervention to evaluate changes in symptoms and related biological markers. The goal of this study is to better understand shared mechanisms between joint pain and cognitive health and to explore whether a ketogenic dietary approach may support symptom management in these populations.",[114,112,113,28,631,632,633,634],"Mild Cognitive Impairment","MCI","Mild Cognitive Impairment (MCI)","Dementia",[636,527,116,637],"ketogenic diet","mild cognitive impairment","2026-04-30",{"date":610,"type":34},{"date":641,"type":22},"2026-06-01",{"date":643,"type":22},"2027-06-01",{"name":645,"class":99},"University of Kansas Medical Center",{"id":647,"slug":648,"hasResults":12,"nctId":649,"briefTitle":650,"officialTitle":651,"acronym":652,"eligibilityCriteria":653,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":654,"targetDuration":4,"studyType":23,"phases":656,"briefSummary":657,"conditions":658,"keywords":664,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":666,"lastUpdatePostDateStruct":667,"startDateStruct":668,"completionDateStruct":669,"leadSponsor":671,"locationsCount":128},"100635374","manual-arthroplasty-versus-velys-robotic-assisted-solution-functional-alignment-arthroplasty-for-knee-osteoarthritis-100635374","NCT07551856","Manual Arthroplasty Versus VELYS Robotic-Assisted Solution Functional Alignment Arthroplasty for Knee Osteoarthritis","Manual Arthroplasty Versus VELYS Robotic-Assisted Solution Functional Alignment Arthroplasty for Knee Osteoarthritis (The MARVEL Project): A Pragmatic, Multicentre, Blinded Randomised Controlled Trial With Multi-domain Investigations","MARVEL Project","Inclusion Criteria:\n\n* Aged \\>18 years\n* Primary knee OA\n* Requiring TKA\n* Suitable for either raTKA or mTKA\n* Capable to provide written informed consent\n* Capable and willing to complete outcome measures throughout study period\n\nExclusion Criteria:\n\n* Inflammatory arthritis\n* Significant symptomatic hip, ankle, or contralateral knee OA\n* Prior TKA or major injury or major surgery on the index knee\n* Neuromuscular gait disorders\n* BMI \\>45 kg\u002Fm2\n* Coronal plane deformity \\>15° varus\u002Fvalgus on pre-op HKA radiograph\n* Fixed flexion deformity greater than 15°\n* Bone loss likely to require non-standard implants (e.g. stems, augments)\n* Severe deformity or ligament insufficiency likely to require constraint\n* Inability to comply with the required follow-up assessments or complete PROMs\n* Contraindications to any aspect of the surgical technique",{"count":655,"type":22},346,[84],"The goal of this clinical trial is to learn if the VELYS Robotic-Assisted Solution (VRAS) device helps to improve outcomes from total knee replacement, when compared to regular non-robotic-assisted total knee replacement in the treatment of osteoarthritis. It will also aim to review the longer-term safety and efficiency effects of using this device.\n\nThe main questions it aims to answer are:\n\n1. Does VRAS device-assisted total knee replacement improve patient outcomes (such as their function, satisfaction, and pain) when compared to non-robotic-assisted total knee replacement?\n2. Does VRAS device-assisted total knee replacement improve clinical outcomes (such as revision risk, complications, and hospital length of stay) when compared to non-robotic-assisted total knee replacement?\n3. Does VRAS device-assisted total knee replacement improve functional outcomes (including biomechanical motion analysis) when compared to non-robotic-assisted total knee replacement?\n4. What are the economic and efficiency effects of VRAS device-assisted total knee replacement compared to non-robotic-assisted total knee replacement?\n5. What are the human factor and learning curve effects of introducing VRAS device-assisted total knee replacement into healthcare teams?\n6. Are there any differences in safety and adverse event incidence between VRAS device-assisted total knee replacement and non-robotic-assisted total knee replacement?\n\nParticipants will:\n\n* Be randomised to receive a total knee replacement using either regular non-robotic-assisted methods, or with the use of the VRAS device.\n* Be assessed pre-operatively at the clinic, and then at 6 weeks, 6 months, and 12 months following date of operation. At these appointments patients will answer questionnaires, receive an x-ray (pre-operatively, and at 6 months post-operatively), and a subgroup will be reviewed in the motion analysis laboratory (pre-operatively, and at 6 months post-operatively).\n* Have their longer-term outcomes including any revision operations monitored out to 10 years through national registry data linkage (no actual follow-up for patients after 12 months).",[222,659,660,661,662,28,663],"Osteoarthritis (Knee)","Osteo Arthritis of the Knee","Osteo Arthritis","Osteoarthritis (OA)","Osteoarthritis in the Knee",[428,28,581,665],"Alignment","2026-04-28",{"date":610,"type":34},{"date":585,"type":22},{"date":670,"type":22},"2030-05-08",{"name":672,"class":673},"Golden Jubilee National Hospital","OTHER_GOV"]